Table 1.
Study | Medication (duration of use) | Healthy controls, no. | Neuroimaging method | Task | Neural effects |
---|---|---|---|---|---|
Loubinoux et al.26 | Fluoxetine (short-term) Fenzole (short-term) | 12 | fMRI |
|
|
Loubinoux et al.27 | Paroxetine (1 mo) | 19 | fMRI |
|
|
Peran et al.28 | Paroxetine (4 mo) | 12 | fMRI |
|
|
Del-Ben et al.29 | Citalopram (short-term) | 12 | fMRI |
|
|
Murphy et al.30 | Citalopram (short-term) | 26 | fMRI |
|
|
Harmer et al.32 | Citalopram (7 d) | 24 | fMRI |
|
|
Arce et al.31 | Escitalopram (21 d) | 13 | fMRI |
|
|
Mintzer et al.38 | Triazolam (short-term) | 15 | PET150 – H2O |
|
|
Mintzer et al.39 | Triazolam (short-term) | 12 | PET150 – H2O |
|
|
Paulus et al.40 | Lorazepam (short-term) | 15 | fMRI |
|
|
Norbury and Mackay37 | Reboxetine (7 d) | 24 | fMRI |
|
|
Kleinschmidt et al.41 | Methamphetamine (short-term) | 7 | fMRI |
|
|
Holcomb et al.42 | Ketamine (short-term) | 23 | PET H215O |
|
|
Holcomb et al.42 | Ketamine (short-term) | 8 | fMRI |
|
|
Li et al.44 | Lamotrigine (short-term) | 12 | TMS/fMRI |
|
BA = Brodmann area; BOLD = blood oxygen level–dependent; fMRI = functional magnetic resonance imaging; PET = positron emission tomography; TMS = transcranial magnetic stimulation.